CO6811851A2 - Formulación que comprende derivado de fenilaminopirimidina como agente activo - Google Patents

Formulación que comprende derivado de fenilaminopirimidina como agente activo

Info

Publication number
CO6811851A2
CO6811851A2 CO13236457A CO13236457A CO6811851A2 CO 6811851 A2 CO6811851 A2 CO 6811851A2 CO 13236457 A CO13236457 A CO 13236457A CO 13236457 A CO13236457 A CO 13236457A CO 6811851 A2 CO6811851 A2 CO 6811851A2
Authority
CO
Colombia
Prior art keywords
formulation
active agent
phenylaminopyrimidine derivative
phenylaminopyrimidine
derivative
Prior art date
Application number
CO13236457A
Other languages
English (en)
Inventor
Durga Maheswari Parvatanemi
Siddhartha Yedluri
Venkata Satyanarayana Appadwedula
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43923331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6811851(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of CO6811851A2 publication Critical patent/CO6811851A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CO13236457A 2011-03-07 2013-10-04 Formulación que comprende derivado de fenilaminopirimidina como agente activo CO6811851A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1103860.1A GB2488788B (en) 2011-03-07 2011-03-07 Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response

Publications (1)

Publication Number Publication Date
CO6811851A2 true CO6811851A2 (es) 2013-12-16

Family

ID=43923331

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13236457A CO6811851A2 (es) 2011-03-07 2013-10-04 Formulación que comprende derivado de fenilaminopirimidina como agente activo

Country Status (32)

Country Link
US (1) US9895367B2 (es)
EP (1) EP2683381B1 (es)
JP (1) JP5788534B2 (es)
KR (1) KR101767296B1 (es)
CN (1) CN103561742B (es)
AP (1) AP4076A (es)
AU (1) AU2011361921B2 (es)
BR (1) BR112013022930A2 (es)
CA (1) CA2829015C (es)
CO (1) CO6811851A2 (es)
CY (1) CY1116968T1 (es)
DK (1) DK2683381T3 (es)
EA (1) EA024610B1 (es)
ES (1) ES2554927T3 (es)
GB (1) GB2488788B (es)
GE (1) GEP20156410B (es)
HR (1) HRP20151382T1 (es)
HU (1) HUE025562T2 (es)
IL (1) IL228218A (es)
MA (1) MA35088B1 (es)
MX (1) MX339130B (es)
MY (1) MY158693A (es)
NZ (1) NZ614903A (es)
PL (1) PL2683381T3 (es)
PT (1) PT2683381E (es)
RS (1) RS54420B1 (es)
SG (1) SG193349A1 (es)
SI (1) SI2683381T1 (es)
SM (1) SMT201500235B (es)
UA (1) UA111074C2 (es)
WO (1) WO2012120328A1 (es)
ZA (1) ZA201306643B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3389633T (lt) * 2015-12-18 2021-09-10 Natco Pharma Ltd Farmacinės kompozicijos, apimančios fenilaminopirimidino darinį
EP3397242B1 (en) * 2015-12-29 2021-02-03 Noivita S.R.L.S. Lipophilic formulations
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
CN107564610A (zh) * 2017-10-20 2018-01-09 浙江中大元通特种电缆有限公司 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆
MX2020009438A (es) 2018-03-14 2022-05-11 Kandy Therapeutics Ltd Formulacion farmaceutica novedosa que comprende antagonistas del receptor dual nk-1/nk-3.
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
EP0999826B1 (en) * 1997-07-29 2004-05-06 PHARMACIA & UPJOHN COMPANY Self-emulsifying formulation for lipophilic compounds
US6248354B1 (en) 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
EP1786799B1 (en) * 2004-09-09 2012-07-04 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
JP2009514988A (ja) * 2006-10-26 2009-04-09 シコール インコーポレイティド イマチニブ塩基及びイマチニブメシレート、及びそれらの調製方法
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
WO2008134731A1 (en) * 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
MX2010009401A (es) * 2008-03-04 2010-09-24 Natco Pharma Ltd Forma cristalina de derivado de fenilamino pirimidina.
WO2010068311A1 (en) * 2008-05-23 2010-06-17 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein inhibitor

Also Published As

Publication number Publication date
AU2011361921A2 (en) 2014-10-30
AP4076A (en) 2017-03-23
ES2554927T3 (es) 2015-12-28
CN103561742A (zh) 2014-02-05
EA024610B1 (ru) 2016-10-31
HUE025562T2 (en) 2016-03-29
SI2683381T1 (sl) 2016-01-29
NZ614903A (en) 2014-08-29
EP2683381B1 (en) 2015-09-16
HRP20151382T1 (hr) 2016-02-12
BR112013022930A2 (pt) 2016-12-06
RS54420B1 (en) 2016-04-28
ZA201306643B (en) 2014-11-26
CA2829015C (en) 2018-01-02
KR101767296B1 (ko) 2017-08-10
US20130338180A1 (en) 2013-12-19
MY158693A (en) 2016-11-15
PL2683381T3 (pl) 2016-06-30
AP2013007128A0 (en) 2013-09-30
KR20140016926A (ko) 2014-02-10
WO2012120328A1 (en) 2012-09-13
MA35088B1 (fr) 2014-05-02
CA2829015A1 (en) 2012-09-13
UA111074C2 (uk) 2016-03-25
SMT201500235B (it) 2015-10-30
AU2011361921A1 (en) 2013-09-26
GEP20156410B (en) 2015-12-10
PT2683381E (pt) 2015-11-02
JP2014507463A (ja) 2014-03-27
GB2488788B (en) 2013-07-10
SG193349A1 (en) 2013-10-30
JP5788534B2 (ja) 2015-09-30
CY1116968T1 (el) 2017-04-05
DK2683381T3 (en) 2015-12-21
MX339130B (es) 2016-05-13
EA201391280A1 (ru) 2014-02-28
GB2488788A (en) 2012-09-12
GB201103860D0 (en) 2011-04-20
US9895367B2 (en) 2018-02-20
MX2013010160A (es) 2013-12-06
IL228218A (en) 2016-06-30
CN103561742B (zh) 2016-04-27
EP2683381A1 (en) 2014-01-15
AU2011361921B2 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
IL251647B (en) Oral veterinary preparations for the treatment of parasites containing active factors that act systemically
CO6910187A2 (es) Composiciones parasiticidas que comprenden un agente activo isoxazolina, sus métodos y usos
BR112013013311A2 (pt) agente terapêutico de indução de citotoxicidade
CL2014002700A1 (es) Composición herbicida que comprende como ingrediente activo, un compuesto de uracilo
CO6811868A2 (es) Combinaciones de principios activos
BR112014009634A2 (pt) preparação e agente terapêutico
DK2900645T3 (da) Herbicidt aktive 3-phenylisoxazolinderivater
BR112014029123A2 (pt) composições compreendendo um agente de controle biológico e um inseticida
CR20130403A (es) Derivados de fluoro-piridinona útiles como agentes antibacterianos
CO7061076A2 (es) Composición farmacéutica que contiene un derivado de dihidroquinazolina antiviralmente activo
CO6870038A2 (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CO6852077A2 (es) Composiciónes que comprenden ditiínas sustituidas fungicidas y compuestos activos adicionales
BR112014000015A2 (pt) formulação
SMT201500235B (it) Formulazione comprendente derivato di fenilamminopirimidina come agente attivo
DK2868318T4 (da) Injicerbar formulering
PL2897984T3 (pl) Wodna kompozycja emulsyjna nadtlenku organicznego
ZA201504967B (en) Transdermal dosage form for low-melting point active agent
CO6910203A2 (es) Aditivo de azúcar concentrado como agente antipolvillo
PL2836580T3 (pl) Mikrofibrylarna celuloza jako substancja czynna zdolna do odrywania brudu
CO6801765A2 (es) Isoxazolinas como agentes terapéuticos
DE112013005825A5 (de) Reduktionsmittelzuführeinrichtung
BR112014027708A2 (pt) formulação de tobramicina
DK3251507T3 (da) Forbedrede insekticidformuleringer
ITRE20110042A1 (it) Agente sanitario
CL2014000353A1 (es) Mezclas activas de insecticidas que comprenden compuestos de arilquinozalinona